Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
EZZ Life Science Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.87M | 66.87M | 66.44M | 37.14M | 15.02M | 22.29M |
| Gross Profit | 49.72M | 49.72M | 50.95M | 27.20M | 7.51M | 12.46M |
| EBITDA | 10.08M | 11.10M | 10.38M | 5.09M | 1.90M | 2.87M |
| Net Income | 6.73M | 6.73M | 6.96M | 3.63M | 1.31M | 2.03M |
Balance Sheet | ||||||
| Total Assets | 33.96M | 33.96M | 25.55M | 17.64M | 14.27M | 12.04M |
| Cash, Cash Equivalents and Short-Term Investments | 20.85M | 20.85M | 19.02M | 13.83M | 10.46M | 8.85M |
| Total Debt | 304.49K | 304.49K | 123.86K | 478.59K | 104.57K | 79.01K |
| Total Liabilities | 5.87M | 5.87M | 4.23M | 3.06M | 2.88M | 1.93M |
| Stockholders Equity | 28.09M | 28.09M | 21.32M | 14.58M | 11.39M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | 4.13M | 4.09M | 5.73M | 3.91M | 1.89M | 237.42K |
| Operating Cash Flow | 4.37M | 4.35M | 6.14M | 4.01M | 1.90M | 253.53K |
| Investing Cash Flow | -546.93K | -546.93K | -441.17K | -101.78K | -13.18K | -16.12K |
| Financing Cash Flow | -2.17M | -2.17M | -582.45K | -761.72K | -277.36K | 5.44M |
EZZ Life Science Holdings Ltd. Technical Analysis
EZZ Life Science Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$68.17M | 9.91 | 27.24% | 2.76% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$64.13M | -6.22 | -27.39% | ― | ― | 26.64% | |
44 Neutral | AU$172.06M | -6.60 | ― | ― | ― | 0.66% | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% | |
41 Neutral | AU$96.19M | -0.96 | -83.09% | ― | ― | 55.94% | |
40 Underperform | AU$91.29M | -11.18 | -47.98% | ― | 700.00% | 26.88% |
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Holdings Limited announced the cessation of Glenn Cross as a director effective 28 November 2025. This change in the board may influence the company’s strategic direction and could have implications for its stakeholders, as Cross held significant interests in the company, including 45,000 fully paid ordinary shares and 10,000 performance rights.
EZZ Life Science Holdings Limited has appointed Glenn Cross as Chief Strategy Officer after his tenure as Chair of the Board. With over 40 years of experience in the life-science sector, Cross will continue to contribute to EZZ’s strategic initiatives, including product development and international expansion, particularly in the United States. The company is also seeking a new Non-Executive Chair to support its evolving global footprint.
EZZ Life Science Holdings Limited announced the results of its Annual General Meeting, where the re-election of Mr. Glenn Cross as a director was withdrawn following his decision not to stand for re-election. The board expressed gratitude for his contributions, and CEO Mark Qin will serve as interim Chair. The announcement reflects ongoing leadership changes and strategic adjustments within the company, potentially impacting its governance and operational strategies.
EZZ Life Science Holdings Limited announced the results of its Annual General Meeting, where the re-election of Mr. Glenn Cross as Director was withdrawn. Mr. Cross decided not to stand for re-election, and the company expressed gratitude for his contributions. CEO Mark Quinn will serve as interim Chair. The meeting also included the approval of a 7.1A mandate and the adoption of a remuneration report, reflecting ongoing governance and strategic adjustments within the company.
EZZ Life Science Holdings Limited reported strong financial performance for FY25, with revenue reaching $66.9 million and a significant presence in Southeast Asia. The company achieved strategic milestones, including entering the U.S. market with FDA-registered products and expanding its Southeast Asian footprint through a distribution agreement. EZZ also launched 15 new products and enhanced its domestic retail presence. With a robust balance sheet and expanding international reach, EZZ is poised for sustained growth and enhanced shareholder value in FY26.
EZZ Life Science Holdings Limited has announced a fully franked final dividend of $0.020 per share for the fiscal year ending 30 June 2025. The dividend will be paid on 23 December 2025, with an ex-dividend date of 24 November 2025 and a record date of 25 November 2025. This announcement reflects the company’s commitment to rewarding shareholders and may enhance its attractiveness to investors.
EZZ Life Science Holdings Limited reported its quarterly activities and financials for Q1 FY26, highlighting strategic progress in market expansion and product innovation. The company made significant strides in the US market by shifting its marketing strategy towards performance-driven campaigns and expanding its retail channels, including discussions to enter the Walmart Marketplace. Domestically, EZZ expanded its pharmacy network and launched a new Shopify store to boost its retail presence in Australia. Despite a 25.4% drop in customer receipts due to deferred payments and seasonal factors in China, EZZ maintained a strong cash position of $17.3 million and remains debt-free. The company launched three new health products, reinforcing its competitive edge and commitment to innovation. Looking forward, EZZ aims to scale its brand in the US, drive growth in Southeast Asia, and continue expanding its Australian retail channels.
EZZ Life Science Holdings Ltd. has announced its Annual General Meeting (AGM) scheduled for November 28, 2025. The company will provide meeting materials electronically, following recent legislative changes, to enhance accessibility and environmental sustainability. Shareholders are encouraged to participate and submit their votes in advance through various online and offline channels.
EZZ Life Science Holdings Ltd. has announced its Annual General Meeting to be held on November 28, 2025. Key agenda items include the consideration of financial statements, the adoption of the remuneration report, the re-election of director Glenn Cross, and the approval of a mandate to issue equity securities. These resolutions are significant as they impact the company’s governance and capital structure, potentially influencing shareholder value and strategic direction.
EZZ Life Science Holdings Limited has announced the date for its 2025 Annual General Meeting, which will be held on November 28, 2025. The company has also set October 17, 2025, as the closing date for director nominations. This announcement is part of EZZ’s ongoing efforts to strengthen its governance and strategic positioning in the genomic life sciences sector.